Shots:
- Innovent & Eli Lilly have entered into a strategic collaboration to advance novel medicines in oncology & immunology
- As per the deal, Innovent will advance the programs from discovery through P-II PoC trial in China using its antibody platforms, while Lilly will receive exclusive rights to develop & commercialize the assets globally, excl. Greater China, with Innovent retaining regional rights
- As per the deal, Innovent will receive $350M upfront & ~$8.5B in development, regulatory & commercial milestones, with tiered royalties on net sales of each product outside of Greater China
Ref: Innovent  |  Image: Innovent & Eli Lilly  | Press Release
Related News: Innovent’s Tabosun (Ipilimumab N01) Receives the NMPA approval for MSI-H/dMMR Resectable Colon Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
